HRP20020334B1 - Process for the preparation of amorphous atorvastatin calcium - Google Patents
Process for the preparation of amorphous atorvastatin calciumInfo
- Publication number
- HRP20020334B1 HRP20020334B1 HR20020334A HRP20020334A HRP20020334B1 HR P20020334 B1 HRP20020334 B1 HR P20020334B1 HR 20020334 A HR20020334 A HR 20020334A HR P20020334 A HRP20020334 A HR P20020334A HR P20020334 B1 HRP20020334 B1 HR P20020334B1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- atorvastatin calcium
- amorphous atorvastatin
- atorvastatin
- heating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title 1
- 229960001770 atorvastatin calcium Drugs 0.000 title 1
- BWFCZHDTTAYGNN-CNZCJKERSA-N calcium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound [Ca].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 BWFCZHDTTAYGNN-CNZCJKERSA-N 0.000 abstract 3
- 238000010438 heat treatment Methods 0.000 abstract 2
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903634A HU226640B1 (en) | 1999-10-18 | 1999-10-18 | Process for producing amorphous atorvastatin calcium salt |
| PCT/HU2000/000106 WO2001028999A1 (en) | 1999-10-18 | 2000-10-17 | Process for the preparation of amorphous atorvastatin calcium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20020334A2 HRP20020334A2 (en) | 2004-02-29 |
| HRP20020334B1 true HRP20020334B1 (en) | 2007-12-31 |
Family
ID=90014241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020334A HRP20020334B1 (en) | 1999-10-18 | 2002-04-15 | Process for the preparation of amorphous atorvastatin calcium |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1235800B1 (de) |
| JP (1) | JP2003512354A (de) |
| KR (1) | KR100664353B1 (de) |
| CN (1) | CN1157374C (de) |
| AT (1) | ATE345327T1 (de) |
| AU (1) | AU1166301A (de) |
| CA (1) | CA2388018C (de) |
| CZ (1) | CZ300071B6 (de) |
| DE (1) | DE60031882T2 (de) |
| HK (1) | HK1050199A1 (de) |
| HR (1) | HRP20020334B1 (de) |
| HU (1) | HU226640B1 (de) |
| PL (1) | PL354604A1 (de) |
| RS (1) | RS50473B (de) |
| RU (1) | RU2255932C2 (de) |
| SK (1) | SK286861B6 (de) |
| UA (1) | UA72777C2 (de) |
| WO (1) | WO2001028999A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| DE10135493A1 (de) * | 2001-07-20 | 2003-01-30 | Jobst Krauskopf | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
| CZ2004126A3 (cs) | 2001-07-30 | 2004-12-15 | Dr. Reddy's Laboratories Limited | Krystalické formy VI. A VII. vápenaté soli atorvastatinu |
| ATE452871T1 (de) * | 2002-03-18 | 2010-01-15 | Biocon Ltd | Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| CA2627940A1 (en) | 2004-03-17 | 2005-10-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| MXPA06011987A (es) * | 2004-04-16 | 2007-01-16 | Pfizer Prod Inc | Procedimiento para formar calcio de atorvastatina amorfa. |
| CN1692906A (zh) * | 2004-04-30 | 2005-11-09 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
| EP1745020A2 (de) | 2004-05-05 | 2007-01-24 | Pfizer Products Incorporated | Salzformen von atorvastatin |
| CA2573771C (en) | 2004-07-20 | 2011-05-10 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| TW200825092A (en) | 2004-09-28 | 2008-06-16 | Teva Pharma | A method for reducing the level of AED in atorvastatin calcium sample |
| TW200942516A (en) * | 2004-10-18 | 2009-10-16 | Teva Pharma | Processes for preparing amorphous atorvastatin hemi-calcium |
| BRPI0519996A2 (pt) | 2004-10-28 | 2009-04-07 | Warner Lambert Co | processo para formar atorvastatina amorfa |
| DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
| EP1810667A1 (de) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN103274985B (zh) * | 2010-12-03 | 2016-03-09 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| BR9712072A (pt) * | 1996-09-20 | 1999-08-24 | Meiji Seika Kaisha | Subst-ncia cristalina de defditoren pivoxil e a produ-Æo da mesma |
-
1999
- 1999-10-18 HU HU9903634A patent/HU226640B1/hu not_active IP Right Cessation
-
2000
- 2000-10-17 UA UA2002054059A patent/UA72777C2/uk unknown
- 2000-10-17 CZ CZ20021256A patent/CZ300071B6/cs not_active IP Right Cessation
- 2000-10-17 EP EP00973115A patent/EP1235800B1/de not_active Expired - Lifetime
- 2000-10-17 PL PL00354604A patent/PL354604A1/xx not_active Application Discontinuation
- 2000-10-17 SK SK519-2002A patent/SK286861B6/sk not_active IP Right Cessation
- 2000-10-17 JP JP2001531799A patent/JP2003512354A/ja active Pending
- 2000-10-17 KR KR1020027004906A patent/KR100664353B1/ko not_active IP Right Cessation
- 2000-10-17 RU RU2002113564/04A patent/RU2255932C2/ru not_active IP Right Cessation
- 2000-10-17 WO PCT/HU2000/000106 patent/WO2001028999A1/en active IP Right Grant
- 2000-10-17 CA CA002388018A patent/CA2388018C/en not_active Expired - Fee Related
- 2000-10-17 DE DE60031882T patent/DE60031882T2/de not_active Expired - Fee Related
- 2000-10-17 AT AT00973115T patent/ATE345327T1/de not_active IP Right Cessation
- 2000-10-17 AU AU11663/01A patent/AU1166301A/en not_active Abandoned
- 2000-10-17 RS YUP-283/02A patent/RS50473B/sr unknown
- 2000-10-17 CN CNB008144583A patent/CN1157374C/zh not_active Expired - Fee Related
-
2002
- 2002-04-15 HR HR20020334A patent/HRP20020334B1/xx not_active IP Right Cessation
-
2003
- 2003-04-04 HK HK03102420A patent/HK1050199A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RS50473B (sr) | 2010-03-02 |
| DE60031882T2 (de) | 2007-07-05 |
| CZ300071B6 (cs) | 2009-01-21 |
| KR100664353B1 (ko) | 2007-01-02 |
| EP1235800A1 (de) | 2002-09-04 |
| HUP9903634A3 (en) | 2002-01-28 |
| SK286861B6 (sk) | 2009-06-05 |
| WO2001028999A1 (en) | 2001-04-26 |
| KR20020063166A (ko) | 2002-08-01 |
| HUP9903634D0 (en) | 1999-12-28 |
| CN1157374C (zh) | 2004-07-14 |
| PL354604A1 (en) | 2004-01-26 |
| SK5192002A3 (en) | 2002-11-06 |
| HK1050199A1 (en) | 2003-06-13 |
| ATE345327T1 (de) | 2006-12-15 |
| DE60031882D1 (de) | 2006-12-28 |
| YU28302A (sh) | 2005-06-10 |
| EP1235800B1 (de) | 2006-11-15 |
| CN1379760A (zh) | 2002-11-13 |
| CA2388018A1 (en) | 2001-04-26 |
| RU2255932C2 (ru) | 2005-07-10 |
| AU1166301A (en) | 2001-04-30 |
| HUP9903634A2 (hu) | 2001-12-28 |
| CZ20021256A3 (cs) | 2002-08-14 |
| UA72777C2 (en) | 2005-04-15 |
| CA2388018C (en) | 2008-04-08 |
| JP2003512354A (ja) | 2003-04-02 |
| HRP20020334A2 (en) | 2004-02-29 |
| HU226640B1 (en) | 2009-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020334B1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| JP2003512354A5 (de) | ||
| BR9907936A (pt) | Composição farmacêutica, composto, e, processo para preparar o mesmo | |
| HRP20050895B1 (hr) | Ftalazinon derivati | |
| ATE243672T1 (de) | Neue thyroid-rezeptorliganden und verfahren | |
| RS54573B1 (en) | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS | |
| EA199900083A1 (ru) | Замещенные пиридо- или пиримидосодержащие 6,6 или 6,7-бициклические производные | |
| CY1112100T1 (el) | ΝΕΑ ΕΝΩΣΗ ΤΡΙΣΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8Η-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-7-ΟΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΑΣΘΕΝΕΙΩΝ, ΟΙ ΟΠΟΙΕΣ ΕΧΟΥΝ ΠΡΟΚΛΗΘΕΙ ΜΕ ΤΗ ΜΕΣΟΛΑΒΗΣΗ CSBP/p38 ΚΙΝΑΣΗΣ | |
| DE69203877D1 (de) | Verfahren zur Vernichtung von photokatalytisch abbaubarem, organischem Stoff. | |
| DK1102739T3 (da) | Glucocorticoid- og thyroidhormonreceptorligander til behandling af metaboliske lidelser | |
| EA200200510A1 (ru) | 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр | |
| DE69821376D1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
| DE69204185D1 (de) | Verdampfer mit Eignung zur Wiedergewinnung von Lösungsmittel. | |
| DE60118956D1 (de) | Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen | |
| NO961693L (no) | Delta16-umettede C17-heterocykliske steroider som er anvendbare som steroid C17-20-lyaseinhibitorer | |
| SE0003476D0 (sv) | Compounds | |
| ATE133669T1 (de) | Mesomorphe verbindung, flüssigkristallzusammensetzung, verfahren und vorrichtung zur flüssigkristallanzeige | |
| DE69303935D1 (de) | Verfahren zur Herstellung von 4-Bromomethylbiphenyl-Verbindungen | |
| SE0004054D0 (sv) | N-type calcium channel antagonists for the treatment of pain | |
| DK0532530T3 (da) | Derivater af 6-amino-octahydroindolizintriol | |
| BRPI0408117A (pt) | compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos | |
| FI923968A (fi) | Heterocykliskt substituerade kinolylmetoxifenylacetamider | |
| ATE428677T1 (de) | Rückgewinnung und recycling chiraler weinsäureverbindungen zur racematspaltung | |
| CY1108756T1 (el) | Μεθοδος για τον καθαρισμο διασερεϊνης | |
| DE60032453D1 (de) | Ein verfahren zur synthese von ritonavir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20081006 Year of fee payment: 9 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20091018 |